Kornimate/medical-research-clean huggingface dataset:
diagnosis of respiratory disorders by the numerical modeling.

Conditions: Nasal Obstruction; Deviated Nasal Septum

Summary: chronic nasal obstruction (cno) is not currently measurable objectively because clinicians use validated declarative self-questionnaires whose results are linked to the level of understanding, the acute or chronic clinical situation, fatigue, psychological state and the desired gain. using numerical simulations of the passage of air in the nasal cavities determining specific airflow parameters, the respiratory comfort of healthy subjects and the cno of patients treated for this pathology could be explained.

cno concerns 20 to 25% of the general population due to numerous etiologies (septal deviation, polyps, chronic rhinosinusitis, post-therapeutic cancer quality of life...). it disrupts sleep and deteriorates all the compartments of the quality of life sometimes to depression. to date, nobody knows the exact component of cno which is probably the amalgamation of different mucosal information and all measurement attempts have failed by lack of reliability and reproducibility. this major shortcoming of cno quantification leads to diagnosis uncertainties, quantification of symptoms and therapeutic. the place of such complementary exam able to do an objective measure of no is expected by the profession. the computational fluid dynamic simulation (cdfs) of the air passage would allow a complementary functional analysis to anatomy of the sino-nasal cavities to measure cno. such information would reduce the failure rate and unnecessary functional surgeries by 25%, reduce the inappropriate care of patients suffering to obstructive sleep disorders and reduce the financial burden on the health system. no patient follow-up in this study: pseudo-anonymized retrospective clinical and scannographic data from the routine management of patients in rhinosinusology consultations.

Eligibility criteria:
inclusion criteria: * 18 years ≤ age \< 70 years * bmi \< 30 kg/m2 * subject or patient of caucasian ethnic origin or from the mediterranean region. * asymptomatic subject with or without a septal deviation without sinonasal disease with a nose score ≤ 7 or patient suffering from chronic nasal obstruction of morphological origin (symptomatic septal or nasoseptal deviation) requiring surgical management with a nose score ≥ 9/20, without or .with sleep apnea with an apnea-hypopnea index ≤ 20 with no other cause than this apnea syndrome exclusion criteria: * acute or chronic rhinosinusitis with or without polyps (except controlled allergic rhinitis) * vasculitis * empty nasal cavity syndrome * septal perforations * history of nasal plastic surgery, sinonasal endoscopic surgery and cancer with head or neck radiotherapy * uncontrolled bronchopulmonary pathology * treatments with nasal vasomotor repercussions.

Keywords: numerical modeling fluid dynamics computer simulation septoplasty nasal air flow sinonasal ct-scan computational fluid dynamic simulation
comparison of efficacy and ocular surface disease assessment between bridin-t eye drops 0.15% and alphagan-p eye drops 0.15% in glaucoma or ocular hypertensive patients : phase 4, parallel group design, investigator-blind, active-control, randomized, multi-center trial

Conditions: Glaucoma; Ocular Hypertensive

Summary: comparison of efficacy and ocular surface disease assessment between bridin-t eye drops 0.15% and alphagan-p eye drops 0.15% in glaucoma or ocular hypertensive patients : phase 4, parallel group design, investigator-blind, active-control, randomized, multi-center trial

following 12 weeks of administration of bridin-t eye drops 0.15%(non preservative) or alphagan-p eye drops 0.15%(preservatives) for patients with glaucoma or ocular hypertensive patients. the use of bridin-t eye drops(non preservative) is less harmful to external ophthalmicus diseases and increase of medication compliance for ophthalmic drugs than the alphagan-p eye drops 0.15%(preservatives)

Eligibility criteria:
inclusion criteria: 1. adult(male or female) over 19 years who were diagnosed with glaucoma or ocular hypertension 2. in the case of a person receiving a glaucoma treatment drug, a person who has completed the appropriate in wash-out period for the existing glaucoma drug before the investigational product is administered. 3. intraocular pressure (iop) \>/= 15mmhg and \< 40mmhg in each eye using goldmann applanation tonometry at visit 2 4. written consent voluntarily to participate in this clinical trial exclusion criteria: 1. patients with primary closed-angle glaucoma, congenital glaucoma and secondary glaucoma caused by steroid drugs, etc. 2. bcva (best-corrected visual acuity) snellen equivalent of snellen 20/80(logmar 0.25) or less. 3. those who have ongoing medical history as intraocular inflamation. 4. central corneal thickness is not between 470um and 591um. 5. patients who have received lacrimal passive occlusion within the last three months or who have surgery plans during the clinical trial period. 6. pregnant or nursing women. 7. patients judged coexisting disease that could interfere with the completion of the treatment or safety of this clinical trial. patients that other researchers are determined inadequately
the effect of training on hemodynamic factors in ballet dancer

Conditions: Venous Insufficiency; Foot Drop (Acquired)

Summary: classic ballet dance is a demonstration of complex motor skills to be revealed in aesthetic combinations and repetitively, and it demands intensive use of the lower extremities within extreme of range of motion (rom). because ballet practice depends on advanced technical skills, it involves intensive physical training and causes an overload on the musculoskeletal system and foot deformities such as pes planus. plantar venous pump (pvp) is a network of multiple venous vessels located between the muscles of the foot arch. pvp is considered the first step of venous return and discharges into the posterior tibial vein (ptv). pvp is reported to be active during gait while it is inactive in resting position. there are different views on the mechanisms enabling its activation 1-3. the general view is that during the stance phase of the gait, the flattening of the plantar arch with weight transfer causes the veins in this region to narrow and creates a force that pumps the blood up. the aim of this study is the investigation what kind of hemodynamic changes ballet training causes in the lower extremity


Eligibility criteria:
inclusion criteria (for balerinas): * receiving ballet training at least 10 h per week for at least 4 years * receiving formal dancing training system inclusion criteria (for non-dancer group) * never receiving formal dancing training * having sedentary lifestyle exclusion criteria: * participants with a history of foot or ankle surgery, * participants with connective tissue disease, * participants with rigid pes planus-cavus, * participants with chronic venous insufficiency * participants with acute ankle injury in recent 3 months
serial oct evaluation of tissue coverage in patients submitted to inspiron drug eluting stent implantation

Conditions: Coronary Artery Disease

Summary: prospective, multicentric, single-arm study to evaluate fast and effective tissue repair in patients undergone percutaneous coronary intervention with drug eluting stent inspiron.

the first 20 patients enrolled will be evaluated by angiography and optical coherence tomography 3 months after stent implantation. the following 20 patients will be evaluated by the same methods 2 months after the implantation and the last 20 patients after 30 days. all patients will be clinically followed at 30 days, 6 months, 1 and 2 years after index procedure.

Eligibility criteria:
inclusion criteria: * age ≥18 and ≤ 80years; * symptomatic cad or documented myocardial ischemic disease; * up to 2 de novo lesions on native coronary arteries; * lesion length ≤ 29mm; * reference vessel diameter between ≥2.5 and ≤ 3.5 mm; * stenose at target lesion ≥ 70% and ≤ 99%. exclusion criteria: * stemi within the last 72 hours pre-procedure; * renal insufficiency; * left main stenosis \> 50%; * ostial lesions; * bifurcation lesions with side branch ≥2mm; * more than one lesion \> 50% at the target vessel; * left ejection fraction less than 30%; * previous (less than 6 months) pci at the target vessel.

Keywords: stent, des, inspiron, oct, tissue repair
proton beam re-irradiation in thoracic cancers

Conditions: Metastatic Malignant Neoplasm in the Lung; Recurrent Disease; Thoracic Neoplasm

Summary: this pilot clinical trial studies proton beam radiation therapy in treating patients with thoracic cancer that has come back and have received prior radiation therapy. proton beam radiation therapy uses high energy protons to kill tumor cells and may cause less damage to normal tissue.

primary objectives: i. to assess the grade 3 toxicity associated with thoracic re-irradiation with proton therapy, with prospectively applied normal organ radiation dose limits. secondary objectives: i. to assess the efficacy of thoracic re-irradiation with proton therapy. outline: patients undergo proton beam radiation therapy per standard of care. after completion of study treatment, patients are followed up at 3 months.

Eligibility criteria:
inclusion criteria: * women of child-bearing age must have a negative pregnancy test * patients must have received prior radiation treatment to the chest; records of prior radiation treatment must be available * patients must have received prior chest radiation at least 3 months prior to enrollment in this trial; radiation treatment to other body sites not overlapping with current radiation fields are allowed within the 3 months period (example, brain radiation is allowed) * patients must have a prior diagnosis of cancer inside the thoracic cavity; both primary thoracic malignancies (such as lung cancer) as well as metastatic lesions (such as metastatic breast cancer or colorectal cancer to the lungs) are allowed; patient must have pathologic confirmation of the recurrent thoracic tumor, or have an enlarging thoracic mass (as seen on two computed tomography \[ct\] scans at least 6 weeks apart, with either a \> 25% or \> 5 mm increase in longest dimension) * patients must have a life expectancy of \> 6 months * patients must have measurable disease to be treated with proton radiation (minimum tumor dimension at least 10 mm on ct imaging) * patients should have either non-metastatic cancer of the thorax, or metastatic cancer to the thorax and candidate for definitive radiation dose to the thoracic tumor (not palliative intent), tumor radiation dose to at least bed2gy 60 gy * patients must be able to receive proton radiation treatment * all stages of cancer are eligible * there are no limits on prior therapy; patients are allowed to have prior chemotherapy and surgery; patients are allowed to have concurrent chemotherapy with radiation treatment; patients are allowed to have chemotherapy or surgery after radiation treatment * patients are allowed to be on another study concurrent with this protocol * ability to understand and the willingness to sign a written informed consent document exclusion criteria: * patients who have never received radiation to the chest * patients who received radiation to the chest within the past 3 months (in a region that overlaps with current radiation fields) * patients with life expectancy \< 6 months * pregnant women * patients unable to provide informed consent * prisoners
development and validation of a risk prediction model for preoperative frailty in elderly patients with colorectal cancer

Conditions: Colorectal Cancer

Summary: fried scale and its related scales were used to analyze the status and risk factors of preoperative frailty in elderly patients with colorectal cancer. r software was used to construct a risk prediction model for preoperative frailty in elderly patients with colorectal cancer, and its validity and stability were verified in clinical practice.


Eligibility criteria:
inclusion criteria: 1. patients who met the diagnostic criteria of colorectal cancer in chinese guidelines for diagnosis and treatment of colorectal cancer 2020 edition and underwent surgery; 2. patients aged ≥60 years old ; 3. patients who are clearly conscious, able to understand instructions, communicate normally, and complete the physical activity ability test without the assistance of others; 4. patients who gave informed consent and volunteered to participate in the study. exclusion criteria: 1. patients with limb joint disease and lower limb pain; 2. patients with serious heart, liver, kidney diseases could not complete the test; 3. patients with visual impairment and hearing impairment; 4. patients with a history of mental illness or drug dependence; 5. taking antidepressants, levodopa/carbidopa, donepezil hydrochloride and other drugs ; 6. patients who received preoperative radiotherapy and chemotherapy; 7. patients with hypothyroidism, parkinson's disease, stroke and other diseases.
colorectal screening strategies in underserved populations

Conditions: Colorectal Cancer

Summary: research efforts are necessary to identify strategies to increase colorectal screening in underserved patient populations. racial, ethnic minorities and medically underserved individuals continue to experience disparities in colorectal cancer mortality despite the availability of screening tests that can detect tumors early when treatments are most effective.

to determine the effectiveness of completion of colorectal cancer screening through fecal testing for blood and/or colonoscopies as a screening intervention utilizing digital reminders versus telephone prompts and reminders in economically disadvantaged minority communities as part of a colorectal screening outreach program.

Eligibility criteria:
inclusion criteria: * any gender * 45-64 years of age * able to sign the informed consent form * meets eligibility criteria to participate in new jersey cancer education early detection community outreach program * uninsured/underinsured * household income \<250% federal poverty level * must be new jersy resident * must have smart phone * must speak english or spanish exclusion criteria: * history of colon cancer, colon/rectal polyps and rectal bleeding * individuals with dementia * ecog performance status 3-4 * prior colonoscopy within past 10 years
a multi-center study to evaluate bone loss, survival rate and stability of ice implant

Conditions: Implant Clinical Survival; Dental Implant Bone Loss

Summary: the current prospective clinical study's aim is to determine abt's ice implant survival rate, crestal interproximal bone resorption during 24 months post implant insertion and to assimilate the drilling sequence during the clinical use of ice implants.


Eligibility criteria:
inclusion criteria: 1. men and women over the age of 18 years who need implantation of 1-4 implants. 2. patients who are able to understand the requirements of the study, and are willing and able to comply with its instructions and schedules. 3. patients who had provided written informed consent to participate in the study prior to any study procedure. 4. patients in general good health in the opinion of the principal investigator as determined by medical history and oral examination. exclusion criteria: 1. immediate loaded implants. 2. treatment with anticoagulant drugs (inr under 1.8) or bisphosphonates. 3. treatment with anticonvulsants drugs. 4. untreated periodontal disease and inability of the patient to maintain reasonable oral hygiene according to study requirements. 5. patients with history of alcohol, narcotics or drug abuse. 6. patients under steroid therapy. 7. patients receiving radiotherapy, chemotherapy or any other immunosuppressive treatment or who have been administered radiotherapy in the last 5 years. patients through at anytime received radiotherapy to the head and neck region will be excluded anyway. 8. metabolic bone disorders and/or bone augmentation. 9. uncontrolled bleeding disorders such as: hemophilia, thrombocytopenia, granulocytopenia. 10. degenerative diseases. 11. osteoradionecrosis. 12. renal failure. 13. organ transplant recipients. 14. hiv positive. 15. malignant diseases. 16. diseases that compromise the immune system. 17. unbalanced diabetes mellitus. (hba1c above 6.5) 18. psychotic diseases. 19. hypersensitivity to one of the components of the implant in general and titanium in particular. 20. women who are pregnant or lactating. 21. lack of patient cooperation. 22. uncontrolled endocrine diseases. 23. any systemic condition that is unbalanced and therefore precludes surgical procedures. 24. parafunctional habits.- e.g bruxism. 25. temporomandibular joint disease. 26. various pathologies of the oral mucosa for example: benign mucous pemphigoid, desquamative ginigivitis, erosive lichen planus ,malignancy of oral cavity, bolus erosive diseases of the oral mucosa. -
a long-term study of ba253bineb in patients with bronchial asthma

Conditions: Asthma

Summary: the objective of this study is to investigate the long-term safety of ba253bineb. secondarily the long-term efficacy of ba253bineb is also investigated.


Eligibility criteria:
inclusion criteria: the patients with bronchial asthma and who satisfy the following criteria 1. patients aged \>= 20 years or older 2. patients with mild to moderate severity 3. patients must be able to understand the patient information form exclusion criteria: 1. patients who have taken an long acting corticosteroids(i.m.) within 1 month before the screening test 2. patients using corticosteroid medication( p.o./ i.h.) at a dose in excess of the equivalent 10 mg/day of prednisolone 3. patients with glaucoma 4. patients who have prostatic hypertrophy 5. patients with hypersensitivity to anticholinergic drugs 6. patients who began treatment with hyposensitization or immunoregulator therapy within 3 month before the screening test 7. patients complicated with chronic bronchitis, emphysema or bronchiectasis, making the assessment of drug efficacy against bronchial asthma difficult 8. patients with serious hepatic disease, kidney disease or heart disorder and who are judged by the investigator as inappropriate as the subjects of study 9. women who are pregnant or who may become pregnant, or nursing women 10. patients who are judged by the investigator as inappropriate as the subjects of the study
stress management and resiliency training (smart) integrated into treatment of major depression

Conditions: Depression

Summary: the investigators are doing this research study to find out if the stress management and resiliency training (smart) therapy will help subjects with their major depression treatment.

the investigators propose to conduct an initial feasibility study in a sample of patients in treatment for major depression using smart. the intervention will be weekly group therapy session of smart for 8 weeks duration. once enrolled, participants will complete a structured clinical interview for diagnosis (scid). the scid will primarily serve to confirm a diagnosis of major depressive disorder. each study intervention group (3-4 groups) will be composed of 6-8 research participants per group. there will be no comparison group. the investigators aim to assess adherence with goal of 75% completion of the 8 sessions of smart and of the homework assignments. resilience will be measured with the connor-davidson resilience scale. secondary outcomes will include subjective and objective clinical rating scales for major depression.

Eligibility criteria:
inclusion criteria: * attending the mayo clinic depression center and behavioral health clinic at mayo clinic health system, austin, minnesota * dsm-v diagnostic confirmation of major depressive disorder (mdd) * baseline phq-9 scores in the range of ≥6-≤19, and hamd-17 score 8-18, or qids-c16 score of 6-20 * able to speak english * participants will continue taking any prescribed medications from their clinical treatment team * patients with co-morbid secondary diagnoses of persistent depressive disorder and generalized anxiety disorders will be included in the study. exclusion criteria: * participants with bipolar disorder * active psychosis * active suicidal ideations * active substance abuse meeting criteria for substance use disorders except nicotine * obsessive compulsive disorder * active panic disorder with agoraphobia, other phobic disorder * active posttraumatic stress disorder * active severe personality disorders.
cognitive interference task on alcohol craving and consumption

Conditions: Alcohol Drinking; Craving

Summary: the purpose of this study is to test a brief task of playing the game tetris to reduce alcohol cravings and alcohol use. women who are seen at primary care and recruited through the community will be asked to rate alcohol craving and use for a 1-week baseline period. then they will be randomly assigned to play the tetris game on their phones daily or to a control condition for a 2-week period. participants will also complete a cue-reactivity task, that involves viewing pictures of alcohol and rating cravings.


Eligibility criteria:
inclusion criteria: 1. female, any race or ethnicity, age 21 to 65 years old. 2. able to comprehend english. 3. at least one heavy drinking per week (i.e., consuming at least four or more drinks in one day) for the last two weeks 4. internet access and reliable electronic device exclusion criteria: 1. more than four heavy drinking days per week. 2. currently engaged in treatment for alcohol use disorder (aud). 3. current clinically significant bipolar affective disorder, schizophrenia, or psychotic disorder. 4. pregnant. 5. imminently suicidal or homicidal. 6. participants taking psychoactive medications that may affect alcohol craving or consumption. 7. a score of 10 or higher on the clinical institute of alcohol withdrawal revised (ciwa-r).24

Keywords: ecological momentary assessment cognitive interference
m89pf in rosacea associated with erythema and sensitive skin

Conditions: Rosacea

Summary: rosacea is a common facial dermatosis, with flares induced by exposome factors. m89pf containing vichy mineralizing water, probiotic fractions, hyaluronic acid, niacinamide and tocopherol repairs the skin barrier and reinforces skin defences against exposome factors. this study assessed the benefit of m89pf in patients with rosacea associated with erythema and sensitive skin during the covid-19 pandemic with use of protective face masks.

m89pf was compared to usual skin care in a randomized, split-face study, for 30 days in subjects with rosacea associated with erythema and sensitive skin. clinical evaluations included erythema, desquamation, skin tightness, dryness, burning sensation, itching, stinging, stinging test, and local tolerability. instrument evaluations included erythema, skin hydration and tewl. subject satisfaction was also assessed.

Eligibility criteria:
inclusion criteria: adult subjects with rosacea associated with erythema and less than 3 papules or pustules and having sensitive skin (positive 15% lactic acid sting test) exclusion criteria: none

Keywords: rosacea skin barrier exposome m89pf splitface sensitive skin
comparison between 2 doses of misoprostol before intrauterine device

Conditions: Pain Relief

Summary: the purpose of the investigators' study was to evaluate whether misoprostol will improve pain scores .

an intrauterine device can cause pain and discomfort in several ways: use of the tenaculum to grasp the cervix and straighten the uterus for proper insertion; trans-cervical actions including measuring uterine depth, inserting the intrauterine device insertion tube, and removing the tube; and placement of the device in the uterus.

Eligibility criteria:
inclusion criteria: * • women not taken analgesics or anxiolytics in the 24 hours prior insertion * women who will accept to participate in the study exclusion criteria: * any contraindication to iud placement